ELEKTA (NASDAQ:EKTAY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday.

According to Zacks, “Elekta AB is a human care company engaged in developing and selling clinical solutions for the treatment of cancer and neurological diseases. It develops tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. The Company’s offering is divided into five areas: Neuroscience, Oncology, Software, Brachytherapy and Services. Elekta AB is headquartered in Stockholm, Sweden. “

ELEKTA (NASDAQ EKTAY) traded up 0.38% during midday trading on Monday, hitting $9.28. The company had a trading volume of 330 shares. ELEKTA has a 52 week low of $7.85 and a 52 week high of $10.95. The firm has a market cap of $3.55 billion and a P/E ratio of 232.00.

COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Upgrades ELEKTA (NASDAQ:EKTAY) to Hold” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/07/zacks-investment-research-upgrades-elekta-nasdaqektay-to-hold.html.

Get a free copy of the Zacks research report on ELEKTA (EKTAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ELEKTA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA and related companies with MarketBeat.com's FREE daily email newsletter.